Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

Imagion Biosystems (ASX: IBX) has announced it will fast-track a new batch of MagSense HER2 imaging agent ahead of a Phase 2 ...

Tyro Payments (ASX:TYR) fell 6% after the Reserve Bank flagged a ban on surcharges across all major payment networks – eftpos ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Olivia Munn has come a long way with her personal experience of breast cancer. Having informed the world of her diagnosis in ...

Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to ...

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.